THE CONNECT SCI STUDY
For People Living with Spinal Cord Injury (SCI)
A clinical trial for individuals with cervical spinal cord injury to evaluate an investigational drug.
About the Study
The CONNECT SCI Study is a randomized, double-blind, placebo-controlled Phase 1b/2a clinical trial of an investigational drug, NVG-291, for people living with spinal cord injury (SCI). This two-part trial is enrolling individuals with chronic and subacute cervical SCI. Enrollment of the chronic group has been completed; approximately 20 individuals will be enrolled in the subacute group. The trial is designed to measure the electrical “connectivity” of nerve pathways to monitor recovery of motor function.
NVG-291 targets the body’s natural inhibitors of repair and in preclinical studies has shown potential in addressing nervous system damage and restoring motor and bladder function. NVG-291 has received Fast Track Designation by the U.S. Food and Drug Administration following the results of a prior Phase 1 trial.
THE CONNECT SCI STUDY
How the Study Works
At the study site at Shirley Ryan AbilityLab in Chicago, participants will receive either a once-daily injection (under the skin) of NVG-291 or placebo for 12 weeks. Regular visits to the trial site during study weeks to complete clinical assessments (blood tests, physical exams, etc.) will be required. The length of the study is 16 weeks and participants will be compensated.
Once-daily Injection for 12 Weeks
Regular Trial Site Visits for Assessments
Study Concludes after 16 Weeks
